Search

Promoting growth

Long-term partner for start-ups

We have already accompanied over 100 start-up projects. We usually acquire a minority share in the resulting companies.

We continue to support our portfolio companies on their growth trajectory and manage our shares as profitably as possible until exit – or, in the case of floatation or takeovers by listed companies, beyond.

We distribute most of our revenues from the sale of equity and shares to the LifeScience Foundation, which in turn makes them available to its endowing institutes as research grants

Current shareholdings

[Translate to English:]

AI-powered precision diagnostics for pathology

Genetic organ modification for solving the problem of organ rejection

Further development of the antitumor chemotherapeutic agent bendamustine

[Translate to English:]

Therapeutics against various autoimmune disorders

[Translate to English:]

RNA hair test for your body clock: Identify your sleeping type & reasons for sleeping problems - Fall asleep better and sleep through the night 

[Translate to English:]

T-cell immunotherapy for untreatable blood cancer patients

[Translate to English:]

Design, research and development of non-coding RNA-based therapeutics for cardiovascular diseases

Translational development and GMP-compliant production of innovative medical radionuclides and tailored chelator systems for radioligand therapy to…

[Translate to English:]

Next level for molecular diagnostics in human skin to improve patients‘ lives and clinical practice in dermatology

[Translate to English:]

Innovative platform technology for the production of new custom-fit antibodies for so far unknown tumor antigens

[Translate to English:]

Discovery and development of new chemical entities for treatment of acute and chronic liver diseases

[Translate to English:]

Novel cell screening technologies for drug development

[Translate to English:]

Qualitative and quantitative measurement of the biological decomposition of toxic waste (contaminated soil)

[Translate to English:]

Novel optoacoustic imaging technology

Development of new therapeutics with the Alginate Film Transmucosal Delivery technology for diseases with high unmet medical needs

[Translate to English:]

Novel CRISPR-based diagnostic platform for multiplexed detection of RNA biomarkers at the point-of-care

Development of a fully automated tissue preserving 3D histopathology platform for clinical use

[Translate to English:]

Development of personalized T cell immunotherapies with a focus on haematological malignancies
Acquisition of Trianta in January 2014

[Translate to English:]

Medtherm GmbH

Advisory service for the application of hyperthermia therapy

[Translate to English:]

Platform to digitize healthcare for all poor countries

[Translate to English:]

Easy-to-use early detection tool for Acute Kidney Injury (AKI)

 

[Translate to English:]

Development of small molecules using an innovative endogenous protective mechanism. Primary focus is the development of a first-in-class oral drug for…

[Translate to English:]

Photoionization mass spectrometry for the direct analysis of complex organic gasses and solids

[Translate to English:]

Diagnosing cortical bone health with ultrasound

Development of ATMPs based on recombinase driven error-free genome editing for eradication of life-threatening virus infection

[Translate to English:]

Improving treatment for patients with severe mental illness through personalized follow-ups

[Translate to English:]

Developing and commercializing ferroptosis modulators for therapeutic use

Development of disruptive non-invasive technologies to measure blood metabolites in humans

[Translate to English:]

Development of T cell receptors (TCRs) for T cell therapy of cancer 

Saliva test to determine the optimal time for chemotherapy

[Translate to English:]

Novel TPH1 inhibitors for serotonin-dependent diseases

[Translate to English:]

AI based software for the prediction and prevention of complications after heart surgery

Therapy for EBV-associated tumors

Former shareholdings

    • Activaero GmbH

    • Bioregeneration GmbH

    • BITZ GmbH

    • Clueda AG

    • eADMET GmbH

    • Encepharm GmbH

    • Genomatix GmbH

    • Inamed GmbH

    • SurgVision B.V.

    • Trianta Immunotherapies GmbH

    • TRION Pharma GmbH

    • Vakzine Projekt Management GmbH

    • WBC Drug Delivery Technologies

    • Zellkraftwerk GmbH

    • Activaero GmbH

    • Alerion

    • amcure GmbH

    • BigChem GmbH

    • Biomax AG

    • Bioregeneration GmbH

    • BITZ GmbH

    • Canopy Biosciences

    • Consentris GmbH

    • Clueda AG

    • CoImmune

    • DentalXrai

    • eADMET GmbH

    • Encepharm GmbH

    • Genomatix GmbH

    • Inamed GmbH

    • NanoRepro AG

    • Spero Therapeutics LLC

    • SurgVision B.V.

    • Trianta Immunotherapies GmbH

    • TRION Pharma GmbH

    • Tube Pharmaceutical GmbH

    • Vakzine Projekt Management GmbH

    • Vectura Group plc

    • WBC Drug Delivery Technologies

    • Zellkraftwerk GmbH

    • amcure GmbH

    • DentalXrai

    • Vectura Group plc

    • Consentris GmbH

    • Tube Pharmaceutical GmbH

    • WBC Drug Delivery Technologies

    • CoImmune